Clinical trial · Interventional
PROspective Trial on EOsinophilia in Non-Small Cell Lung Cancer (NSCLC).
PROspective Trial on EOsinophilia in Non-Small Cell Lung Cancer (NSCLC) (PROTEON).
NCT05602259CI-TRIAL-00073873PROTEONunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This prospective study will examine eosinophils in various biological materials to compare the detection in those materials and ascertain the prognostic and predictive role of eosinophils in untreated non-small cell lung cancer patient.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (4)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood draw | Diagnostic Test | — | UNRESOLVED |
| bronchoalveolar lavage | Diagnostic Test | — | UNRESOLVED |
| induced sputum | Diagnostic Test | — | UNRESOLVED |
| lung biopsy | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Eosinophil detection
- description
- Eosinophils will be measured in blood, sputum, bronchoalveolar lavage if available and biopsies.
- interventionNames
- Diagnostic Test: induced sputum
- Diagnostic Test: lung biopsy
- Diagnostic Test: bronchoalveolar lavage
- Diagnostic Test: blood draw
Primary outcomes (1)
- measure
- Detection of eosinophils in untreated non-small cell lung cancer patients
- timeFrame
- Baseline (pre-treatment)
- description
- Concentration of eosinophils will be used in various bodily materials as described above.
Secondary outcomes (1)
- measure
- Prognostic and predictive value of eosinophils in non-small cell lung cancer patients
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * o All stages of NSCLC * Stage III-IV NSCLC eligible for ICI treatment * 18 years or older; non pregnant women * in stage III-IV: no previous ICI and before ICI (mono- or combination therapy) initiation * Signed informed consent * Clinical, biological and radiological evaluation at the CHU de Liège for at least 6 months following treatment initiation Exclusion Criteria: * Probable noncompliance with the follow-up requirements of the study (psychiatric condition, socio-economic factors) * Inclusion in a clinical study contraindicating the enrolment in the PROTEON study
References
Publications (0)
Data not yet available
No reference posted for this study.